SI-Bone Inc (NASDAQ:SIBN) insider Scott A. Yerby sold 10,133 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $19.61, for a total transaction of $198,708.13. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
SIBN stock opened at $19.73 on Friday. SI-Bone Inc has a 52-week low of $14.08 and a 52-week high of $23.03. The company’s 50 day moving average price is $18.45. The company has a debt-to-equity ratio of 0.47, a current ratio of 13.06 and a quick ratio of 12.70. The firm has a market capitalization of $484.65 million and a price-to-earnings ratio of -27.79.
SI-Bone (NASDAQ:SIBN) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.13). The firm had revenue of $14.99 million for the quarter. Equities research analysts predict that SI-Bone Inc will post -1.45 EPS for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in SIBN. Legal & General Group Plc acquired a new stake in shares of SI-Bone during the fourth quarter valued at approximately $27,000. Citigroup Inc. acquired a new stake in shares of SI-Bone during the fourth quarter valued at approximately $46,000. Valeo Financial Advisors LLC acquired a new stake in shares of SI-Bone during the first quarter valued at approximately $94,000. American International Group Inc. acquired a new stake in shares of SI-Bone during the fourth quarter valued at approximately $115,000. Finally, Deutsche Bank AG acquired a new stake in shares of SI-Bone during the fourth quarter valued at approximately $227,000. Institutional investors and hedge funds own 38.89% of the company’s stock.
Several analysts recently commented on the stock. Zacks Investment Research lowered shares of Yatra Online from a “hold” rating to a “sell” rating in a research note on Saturday, July 6th. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. SI-Bone presently has an average rating of “Buy” and a consensus price target of $24.75.
SI-Bone Company Profile
SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Further Reading: Is the QQQ ETF safe?
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.